{"id":"NCT03932682","sponsor":"Seqirus","briefTitle":"Efficacy Study With QIVc in Pediatric Subjects","officialTitle":"A Phase 3, Randomized, Observer-blind, Multicenter Study to Evaluate the Efficacy, Immunogenicity and Safety of Seqirus' Cell-Based Quadrivalent Subunit Influenza Virus Vaccine (QIVc) Compared to a Non-Influenza Vaccine When Administrated in Healthy Subjects Aged 6 Months Through 47 Months","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-05-13","primaryCompletion":"2023-11-30","completion":"2024-02-13","firstPosted":"2019-05-01","resultsPosted":"2025-03-04","lastUpdate":"2025-03-04"},"enrollment":5723,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza, Human"],"interventions":[{"type":"BIOLOGICAL","name":"QIVc","otherNames":["Flucelvax Quadrivalent"]},{"type":"BIOLOGICAL","name":"Comparator","otherNames":[]}],"arms":[{"label":"QIVc","type":"EXPERIMENTAL"},{"label":"Comparator","type":"ACTIVE_COMPARATOR"}],"summary":"This phase 3 clinical study is a randomized, observer-blind, multicenter study of QIVc versus a non-influenza vaccine in subjects 6 months though 47 months of age. The purpose of this study is to evaluate efficacy of QIVc in the prevention of laboratory confirmed influenza A or B disease in children 6 through 47 months of age, compared to a non-influenza vaccine.","primaryOutcome":{"measure":"Efficacy Endpoint: First Occurrence of Reverse Transcription-polymerase Chain Reaction (RT-PCR) Confirmed Influenza, Due to Any Influenza Type A and/or B Virus Regardless of Antigenic Match","timeFrame":">14 days after last vaccination in the treatment period up to Day 181 or end of influenza season, whichever was longer (previously vaccinated subjects), or up to Day 209 or end of influenza season, whichever was longer (not previously vaccinated subjects)","effectByArm":[{"arm":"QIVc","deltaMin":104,"sd":null},{"arm":"Comparator","deltaMin":173,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":true,"inclusionCount":null,"exclusionCount":7},"locations":{"siteCount":74,"countries":["Bangladesh","Bulgaria","Czechia","Estonia","Honduras","Latvia","Malaysia","New Zealand","Pakistan","Philippines","Poland","Romania","South Africa","Thailand","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":64,"n":2856},"commonTop":["Injection site pain","Injection site erythema","Irritability","Upper respiratory tract infection","Injection site induration"]}}